NASDAQ:BNR - Nasdaq - US12233L2060 - ADR - Currency: USD
NASDAQ:BNR (5/27/2025, 8:04:25 PM)
3.29
+0.04 (+1.23%)
The current stock price of BNR is 3.29 USD. In the past month the price increased by 14.04%. In the past year, price decreased by -53.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.08 | 328.06B | ||
AMGN | AMGEN INC | 13.46 | 150.26B | ||
GILD | GILEAD SCIENCES INC | 14.09 | 135.70B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.53B | ||
REGN | REGENERON PHARMACEUTICALS | 13.61 | 65.13B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.83B | ||
ARGX | ARGENX SE - ADR | 98.77 | 35.40B | ||
ONC | BEIGENE LTD-ADR | 6.1 | 25.76B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.69B | ||
NTRA | NATERA INC | N/A | 21.46B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.04B | ||
BIIB | BIOGEN INC | 8.12 | 18.81B |
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
BURNING ROCK BIOTECH LTD-ADR
No. 5 Xingdao Ring Road North, International Bio Island
Guangzhou GUANGDONG 510005 CN
CEO: Yusheng Han
Employees: 786
Phone: 8618501641666
The current stock price of BNR is 3.29 USD. The price increased by 1.23% in the last trading session.
The exchange symbol of BURNING ROCK BIOTECH LTD-ADR is BNR and it is listed on the Nasdaq exchange.
BNR stock is listed on the Nasdaq exchange.
BURNING ROCK BIOTECH LTD-ADR (BNR) has a market capitalization of 33.75M USD. This makes BNR a Nano Cap stock.
BURNING ROCK BIOTECH LTD-ADR (BNR) currently has 786 employees.
BURNING ROCK BIOTECH LTD-ADR (BNR) has a resistance level at 3.3. Check the full technical report for a detailed analysis of BNR support and resistance levels.
The Revenue of BURNING ROCK BIOTECH LTD-ADR (BNR) is expected to grow by 48.35% in the next year. Check the estimates tab for more information on the BNR EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BNR does not pay a dividend.
BURNING ROCK BIOTECH LTD-ADR (BNR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.72).
The outstanding short interest for BURNING ROCK BIOTECH LTD-ADR (BNR) is 0.63% of its float. Check the ownership tab for more information on the BNR short interest.
ChartMill assigns a technical rating of 2 / 10 to BNR. When comparing the yearly performance of all stocks, BNR is a bad performer in the overall market: 95.25% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to BNR. While BNR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BNR reported a non-GAAP Earnings per Share(EPS) of -4.72. The EPS increased by 94.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -39.16% | ||
ROE | -59.65% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to BNR. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of -277.41% and a revenue growth 48.35% for BNR